Atezolizumab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Colorectal Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Bladder Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
US
  • Alveolar Soft Part Sarcoma (ASPS) for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic ASPS.
Product first approved 2016Outside this platform's coverageFDA label
JP
  • Unresectable, advanced or recurrent non-small cell lung cancer (applicant Chugai)
Product first approved 2018roche.com
EU
  • Urothelial carcinoma (first listed indication); later extended to NSCLC and other cancers
Product first approved 2017EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (93)
Bladder Cancer
NCT03799835 · UNICANCER
2019-01-17 – 2028-10 · Bladder Cancer
What this study did
NCT03775265 · National Cancer Institute (NCI)
2019-06-03 – 2027-11-13 · Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
What this study did
NCT02302807 · Hoffmann-La Roche
2015-01-13 – 2018-11-08 · Bladder Cancer
What this study did
Colorectal Cancer
NCT06733038 · Gruppo Oncologico del Nord-Ovest
2024-11-15 – 2029-04-01 · Colorectal Cancer
What this study did
NCT02997228 · National Cancer Institute (NCI)
2018-01-19 – 2027-06-01 · Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
What this study did
NCT05425940 · Exelixis
2022-09-07 – 2027-01-31 · Colorectal Cancer
What this study did
Hepatocellular Carcinoma
NCT06680258 · Tempest Therapeutics
2025-12 – 2030-07 · Hepatocellular Carcinoma (HCC)
What this study did
NCT07620574 · Exelixis
2026-07-30 – 2030-05-31 · Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC), Differentiated Thyroid Cancer (DTC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Colorectal Cancer, Prostate Cancer
What this study did
NCT07461675 · University of Geneva, Switzerland
2026-03-25 – 2029-12-31 · Hepato Cellular Carcinoma (HCC), Immunotherapy
What this study did
NCT04712643 · Hoffmann-La Roche
2021-03-12 – 2029-02-01 · Hepatocellular Carcinoma
What this study did
NCT05482516 · Georgetown University
2023-03-29 – 2027-12 · Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Adenocarcinoma of Biliary Tract, Gallbladder Adenocarcinoma
What this study did
NCT04803994 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2021-07-06 – 2027-07 · Hepatocellular Carcinoma
What this study did
NCT04770896 · Hoffmann-La Roche
2021-04-26 – 2026-10-14 · Unresectable Hepatocellular Carcinoma
What this study did
Melanoma
NCT03273153 · Hoffmann-La Roche
2017-12-11 – 2021-02-19 · Advanced BRAFV600 Wild-type Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT07388524 · National Cancer Institute (NCI)
2027-03-02 – 2032-09-30 · Lung Non-Small Cell Carcinoma
What this study did
NCT06632327 · Alliance for Clinical Trials in Oncology
2024-12-11 – 2030-04-30 · Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
What this study did
NCT04214262 · National Cancer Institute (NCI)
2020-08-13 – 2027-06-09 · Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
What this study did
NCT05047250 · Hoffmann-La Roche
2022-06-14 – 2027-01-29 · Non-Small Cell Lung Cancer
What this study did
NCT03977194 · Intergroupe Francophone de Cancerologie Thoracique
2019-07-23 – 2026-12 · Non Small Cell Lung Cancer Metastatic
What this study did
NCT03520686 · ImmunityBio, Inc.
2018-05-18 – 2025-10-13 · Non Small Cell Lung Cancer
What this study did
NCT04513925 · Hoffmann-La Roche
2020-08-24 – 2025-07-31 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT03735121 · Hoffmann-La Roche
2018-12-27 – 2024-11-11 · Non-Small Cell Lung Cancer
What this study did
NCT03991403 · Samsung Medical Center
2019-08-27 – 2024-03-11 · Non-small Cell Lung Cancer
What this study did
NCT02813785 · Hoffmann-La Roche
2016-07-01 – 2022-12-27 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT03922997 · Hoffmann-La Roche
2019-07-03 – 2022-08-11 · Non-small Cell Lung Cancer
What this study did
Small Cell Lung Cancer
NCT07947121 · GlaxoSmithKline
2026-12-25 – 2032-03-24 · Lung Neoplasm
What this study did
NCT07625644 · SystImmune Inc.
2026-08-04 – 2031-06 · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc, SCLC,Extensive Stage, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV
What this study did
NCT07472517 · Boehringer Ingelheim
2026-04-13 – 2029-07-30 · Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
What this study did
NCT03811002 · National Cancer Institute (NCI)
2019-07-26 – 2029-02-21 · Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
What this study did
Phase 2/3 (12)
Colorectal Cancer
NCT05770102 · Cancer Research UK
2023-10-25 – 2029-10 · Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Colorectal Neoplasms, Endometrial Neoplasms, Melanoma, Solid Tumours
What this study did
NCT05141721 · Seattle Project Corporation
2022-02-12 – 2027-03 · Colorectal Neoplasms
What this study did
Hepatocellular Carcinoma
NCT07285850 · Eastern Hepatobiliary Surgery Hospital
2025-10-20 – 2026-08-30 · HCC - Hepatocellular Carcinoma
What this study did
NCT05665348 · Federation Francophone de Cancerologie Digestive
2023-03-09 – 2025-05-12 · HCC - Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Tumor
What this study did
Non-Small Cell Lung Cancer
NCT03178552 · Hoffmann-La Roche
2017-09-22 – 2027-06-30 · Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT05722886 · Cancer Research UK
2023-03-01 – 2029-10 · Haematological Malignancy, Solid Tumour
What this study did
NCT05058651 · National Cancer Institute (NCI)
2022-06-28 – 2028-10-01 · Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma, Unresectable Extrapulmonary Neuroendocrine Carcinoma
What this study did
NCT05063552 · National Cancer Institute (NCI)
2023-03-13 – 2027-12-15 · Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Lip and Oral Cavity Carcinoma, Metastatic Nasal Cavity Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Pharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Pharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
What this study did
NCT02839707 · National Cancer Institute (NCI)
2017-06-23 – 2027-05-11 · Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma
What this study did
NCT01810913 · National Cancer Institute (NCI)
2013-03-22 – 2027-01-01 · Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
What this study did
NCT05694013 · Hoffmann-La Roche
2023-02-27 – 2024-06-30 · Cancer
What this study did
Phase 2 (334)
Bladder Cancer
NCT04138628 · Jørgen Bjerggaard Jensen
2020-03-24 – 2030-11-01 · Bladder Cancer, Bladder Cancer, Metastatic
What this study did
NCT04630730 · Swiss Cancer Institute
2022-06-24 – 2030-06 · Bladder Cancer
What this study did
NCT05312671 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2022-06-27 – 2029-10 · Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder
What this study did
NCT03697850 · UNICANCER
2018-12-14 – 2029-02-15 · Bladder Cancer
What this study did
NCT03237780 · National Cancer Institute (NCI)
2018-07-20 – 2027-06-30 · Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma
What this study did
NCT04186013 · Spanish Oncology Genito-Urinary Group
2019-09-18 – 2027-05 · Bladder Cancer
What this study did
NCT03093922 · Memorial Sloan Kettering Cancer Center
2017-03-22 – 2026-09-22 · Urothelial Carcinoma, Locally Advanced, Unresectable
What this study did
NCT04941287 · National Cancer Institute (NCI)
2021-12-15 – 2026-04-29 · Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Recurrent Distal Bile Duct Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Liver Carcinoma
What this study did
NCT04289779 · Deepak Kilari
2020-05-21 – 2025-12 · Bladder Cancer
What this study did
NCT02844816 · National Cancer Institute (NCI)
2017-03-13 – 2024-06-26 · Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7, Stage I Bladder Urothelial Carcinoma AJCC v6 and v7
What this study did
NCT03513952 · National Cancer Institute (NCI)
2019-06-05 – 2024-04-01 · Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma
What this study did
NCT03201458 · National Cancer Institute (NCI)
2018-02-08 – 2024-02-19 · Gallbladder Carcinoma, Metastatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Cholangiocarcinoma
What this study did
NCT05564416 · National Cancer Institute (NCI)
2023-10-12 – 2024-01-01 · Bladder Carcinoma, Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Renal Pelvis and Ureter Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage III Bladder Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Urothelial Carcinoma
What this study did
NCT02091141 · Genentech, Inc.
2014-04-14 – 2023-05-24 · Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer, Bladder Cancer
What this study did
NCT02451423 · Lawrence Fong
2016-03-29 – 2023-03-31 · Carcinoma, Transitional Cell
What this study did
NCT02108652 · Hoffmann-La Roche
2014-05-31 – 2023-02-28 · Bladder Cancer
What this study did
NCT02951767 · Hoffmann-La Roche
2014-05-31 – 2023-02-28 · Bladder Cancer
What this study did
NCT03628716 · Bavarian Nordic
2018-09-18 – 2021-02-02 · Bladder Cancer
What this study did
NCT03620435 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2018-05-01 – 2020-12-30 · Safety Issues
What this study did
NCT02662309 · Queen Mary University of London
2016-02-01 – 2020-06-11 · Bladder Cancer
What this study did
Colorectal Cancer
NCT05999812 · University of Texas Southwestern Medical Center
2023-12-19 – 2028-10-01 · Colorectal Cancer
What this study did
NCT06784947 · University of Colorado, Denver
2025-03-25 – 2028-05 · Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV
What this study did
NCT07235293 · Kahr Bio Australia Pty Ltd
2026-01-16 – 2027-04-30 · Colorectal Cancer
What this study did
NCT05118724 · AIO-Studien-gGmbH
2021-12-10 – 2027-04 · Colorectal Cancer
What this study did
NCT02992912 · Gustave Roussy, Cancer Campus, Grand Paris
2016-11-15 – 2026-06-29 · Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma )
What this study did
NCT05733611 · Replimune, Inc.
2023-06-29 – 2025-08-18 · Refractory Metastatic Colorectal Cancer, pMMR, MSS
What this study did
NCT06603818 · National Cancer Institute (NCI)
2025-08-15 – 2025-08-15 · Microsatellite Stable Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Colorectal Cancer
What this study did
NCT03340558 · Niharika Mettu
2018-05 – 2025-02 · Metastatic Colorectal Cancer
What this study did
NCT05243862 · Treos Bio Limited
2022-06-02 – 2025-01-14 · Colorectal Cancer Metastatic
What this study did
NCT04659382 · Federation Francophone de Cancerologie Digestive
2020-10-07 – 2024-10-31 · Metastatic Colorectal Cancer, pMMR, MSS, Immune Checkpoint Inhibitor, Internal Radiotherapy
What this study did
NCT02873195 · Academic and Community Cancer Research United
2017-07-07 – 2023-12-01 · Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
What this study did
NCT03698461 · Asan Medical Center
2019-05-15 – 2023-10-24 · Colorectal Neoplasms, Neoplasm Metastasis, Colonic Neoplasms, Rectal Neoplasms
What this study did
NCT03721653 · Gruppo Oncologico del Nord-Ovest
2018-11-30 – 2023-08-31 · Metastatic Colorectal Cancer
What this study did
NCT05456165 · Gritstone bio, Inc.
2022-05-19 – 2022-09-01 · Colonic Neoplasms, Colorectal Neoplasms
What this study did
NCT02291289 · Hoffmann-La Roche
2015-04-17 – 2021-03-24 · Colorectal Cancer
What this study did
NCT02982694 · Vall d'Hebron Institute of Oncology
2017-11-24 – 2020-11-27 · MSI, ColoRectal Cancer, Chemotherapy, Resistance, APC
What this study did
Hepatocellular Carcinoma
NCT05620771 · Northwestern University
2022-11-30 – 2040-07-01 · Hepatocellular Carcinoma
What this study did
NCT06605664 · Chang Gung Memorial Hospital
2025-05-01 – 2031-09-30 · Hepatocellular Carcinoma (HCC)
What this study did
NCT07018947 · Fundacion Clinic per a la Recerca Biomédica
2026-06-02 – 2031-06 · Resectable Hepatocellular Carcinoma
What this study did
NCT06339424 · Chang Gung Memorial Hospital
2024-03-30 – 2031-03-30 · Hepatocellular Carcinoma
What this study did
NCT04727307 · University Hospital, Montpellier
2021-02-23 – 2031-02 · Hepatocellular Carcinoma
What this study did
NCT07317414 · Peking Union Medical College Hospital
2025-12-24 – 2030-12-05 · Hepatocellular Carcinoma
What this study did
NCT07239245 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-11-12 – 2030-11-10 · Resectable Hepatocellular Carcinoma With High Risk of Recurrence
What this study did
NCT06133062 · Chang Gung Memorial Hospital
2023-11-16 – 2030-09-30 · Hepatocellular Carcinoma Non-resectable
What this study did
NCT05528952 · Centre Hospitalier Universitaire de Besancon
2022-09-27 – 2030-02-27 · Hepatocellular Carcinoma
What this study did
NCT06789757 · Inova Health Care Services
2025-02-25 – 2030-01-27 · Hepatocellular Carcinoma
What this study did
NCT06254248 · Assistance Publique - Hôpitaux de Paris
2026-01-22 – 2030-01-01 · Liver Transplant, Hepatocellular Carcinoma Recurrent, Systemic Treatment
What this study did
NCT07774247 · CHA University
2026-09-01 – 2029-09-01 · Hepatocellular Carcinoma (HCC)
What this study did
NCT07010497 · Asan Medical Center
2026-03-16 – 2029-03-31 · Carcinoma, Hepatocellular
What this study did
NCT05733598 · Replimune, Inc.
2024-08-01 – 2028-07-01 · Hepatocellular Carcinoma, Biliary Tract Cancer
What this study did
Phase 1/2 (108)
Bladder Cancer
NCT05000294 · University of Florida
2021-12-07 – 2027-06 · Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer
What this study did
NCT02989584 · Memorial Sloan Kettering Cancer Center
2016-12-20 – 2026-12 · Bladder Cancer, Metastatic Bladder Cancer, Urothelial Carcinoma
What this study did
NCT03869190 · Hoffmann-La Roche
2019-06-01 – 2025-12-22 · Urothelial Carcinoma, Bladder Cancer
What this study did
Colorectal Cancer
NCT05944237 · Cancer Research UK
2023-08-02 – 2028-12-31 · Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Mesothelioma, Malignant, Uterine Cervical Neoplasms, Kidney Neoplasms, Sarcoma, Pheochromocytomas
What this study did
NCT03555149 · Hoffmann-La Roche
2018-09-27 – 2022-09-26 · Colorectal Cancer
What this study did
Hepatocellular Carcinoma
NCT05468359 · St. Jude Children's Research Hospital
2022-11-07 – 2037-06 · Refractory Solid Tumor, Hepatocellular Carcinoma, Malignant Solid Tumor, Pediatric Cancer, Pediatric Solid Tumor, Fibrolamellar Carcinoma
What this study did
NCT06725121 · University Health Network, Toronto
2024-12 – 2034-06 · Hepatocellular Carcinoma (HCC), Macrovascular Invasion, Liver Transplant Surgery, Downstaging
What this study did
NCT03942328 · Mayo Clinic
2019-09-19 – 2030-08-31 · Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
What this study did
NCT07835737 · West China Hospital
2026-10-01 – 2029-10-01 · Unresectable Hepatocellular Carcinoma
What this study did
NCT05109052 · University of Rochester
2022-09-20 – 2028-12-31 · Hepatocellular Carcinoma, Cancer of Liver
What this study did
NCT06294548 · University of Alabama at Birmingham
2025-07-29 – 2028-08-28 · Hepatocellular Carcinoma
What this study did
NCT05440708 · Tvardi Therapeutics, Incorporated
2023-03-23 – 2027-07-20 · Hepatocellular Carcinoma
What this study did
NCT05908786 · Hoffmann-La Roche
2023-12-05 – 2025-11-13 · Carcinoma, Hepatocellular
What this study did
NCT06006286 · M.D. Anderson Cancer Center
2023-08-08 – 2023-11-10 · Metastatic Hepatocellular Carcinoma
What this study did
Melanoma
NCT05116202 · Hoffmann-La Roche
2022-02-02 – 2024-05-28 · Melanoma
What this study did
NCT03901573 · NeoImmuneTech
2019-12-26 – 2023-08-15 · Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
What this study did
NCT04123470 · Lokon Pharma AB
2020-01-28 – 2023-07-30 · Malignant Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT04691817 · Abramson Cancer Center at Penn Medicine
2023-07-25 – 2027-09 · Lung Cancer, Nonsmall Cell
What this study did
NCT04467723 · University of Kansas Medical Center
2022-05-18 – 2027-08 · NSCLC Stage IV, NSCLC, Recurrent
What this study did
NCT05501665 · Vanderbilt-Ingram Cancer Center
2023-05-09 – 2027-02-01 · Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer
What this study did
NCT05240131 · Galecto Biotech AB
2022-03-15 – 2025-11-01 · Non-Small Cell Lung Cancer
What this study did
NCT04440735 · Kahr Medical
2020-10-07 – 2025-09 · Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
What this study did
NCT03568656 · CellCentric Ltd.
2018-07-23 – 2025-07-06 · Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
What this study did
NCT04902040 · M.D. Anderson Cancer Center
2021-04-14 – 2025-02-27 · Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Merkel Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT03829501 · Kymab Limited
2019-01-28 – 2024-10-03 · Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer, Gastric Cancer, Melanoma, Renal Cell Carcinoma, Pancreatic Cancer, Cervical Cancer, Triple Negative Breast Cancer, Advanced Cancer, Metastatic Cancer
What this study did
NCT06090318 · Rain Oncology Inc
2023-05-19 – 2023-05-30 · Advanced Solid Tumor, CDKN2A, NSCLC, Urothelial Carcinoma Bladder, Melanoma, Pancreas Adenocarcinoma, HNSCC, Renal Cell Carcinoma, Mesothelioma, Gastric Cancer
What this study did
NCT04471415 · Dracen Pharmaceuticals, Inc.
2020-08-31 – 2023-03-28 · Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic
What this study did
NCT03138889 · Nektar Therapeutics
2017-06-09 – 2022-08-24 · Non-Small Cell Lung Cancer
What this study did
NCT04639245 · Fred Hutchinson Cancer Center
2021-07-19 – 2022-08-16 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT03023423 · Janssen Research & Development, LLC
2016-12-23 – 2019-09-26 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02630186 · Clovis Oncology, Inc.
2016-02-24 – 2017-09-05 · Non-small Cell Lung Cancer
What this study did
Small Cell Lung Cancer
NCT07227597 · Merck Sharp & Dohme LLC
2026-01-29 – 2030-12-30 · Small Cell Lung Cancer Extensive Stage
What this study did
NCT07707895 · Boehringer Ingelheim
2026-11-03 – 2030-04-26 · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
What this study did
NCT06287775 · National Cancer Institute (NCI)
2025-04-08 – 2029-07-25 · Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT07407933 · MediLink Therapeutics (Suzhou) Co., Ltd.
2026-03-31 – 2029-02 · Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
What this study did
NCT05652686 · Phanes Therapeutics
2023-09-05 – 2028-08 · Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
What this study did
NCT05703971 · Genprex, Inc.
2024-05-09 – 2028-06 · Small Cell Lung Cancer Extensive Stage
What this study did
NCT05142696 · Novartis Pharmaceuticals
2022-07-13 – 2028-03-07 · Extensive Stage Small Cell Lung Cancer
What this study did
NCT04471727 · Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2020-12-14 – 2028-01-28 · Small-Cell Lung Cancer, Neuroendocrine Carcinoma
What this study did
NCT06939036 · Ariceum Therapeutics GmbH
2025-07-01 – 2025-12-31 · Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma
What this study did
NCT04487756 · Instituto Oncológico Dr Rosell
2021-03-17 – 2025-09-08 · Extensive-stage Small Cell Lung Cancer
What this study did
NCT04253145 · Fundacion Oncosur
2019-12-13 – 2025-05 · Carcinoma, Small Cell Lung
What this study did
NCT05253053 · TransThera Sciences (Nanjing), Inc.
2022-04-13 – 2024-08-31 · Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer
What this study did
NCT04101357 · BioNTech SE
2020-06-19 – 2024-05-23 · Solid Tumor, Extensive-stage Small Cell Lung Cancer
What this study did
NCT05191797 · University of Washington
2022-04-11 – 2024-04-05 · Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma
What this study did
NCT02748889 · Giuseppe Giaccone
2016-03 – 2017-05-09 · Small Cell Lung Cancer ( SCLC )
What this study did
Other / comorbidity
NCT03424005 · Hoffmann-La Roche
2018-03-30 – 2030-09-30 · Metastatic Breast Cancer
What this study did
Phase 1 (150)
Bladder Cancer
NCT04134000 · Fundacion Oncosur
2020-02-03 – 2024-09 · Invasive Bladder Cancer
What this study did
NCT03650348 · Pieris Pharmaceuticals, Inc.
2018-08-21 – 2022-08-11 · HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer, HER2-positive Solid Tumor
What this study did
NCT03359239 · Matthew Galsky
2019-05-08 – 2021-10-12 · Urothelial/Bladder Cancer, Nos
What this study did
Colorectal Cancer
NCT04929223 · Hoffmann-La Roche
2021-10-22 – 2030-08-31 · Metastatic Colorectal Cancer
What this study did
NCT06012734 · The Netherlands Cancer Institute
2024-06-18 – 2028-07 · Metastatic Microsatellite-stable Colorectal Cancer
What this study did
NCT03845166 · Exelixis
2019-03-20 – 2027-05-31 · Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer
What this study did
NCT04713891 · Keythera Pharmaceuticals (Australia) Pty Ltd
2021-03-09 – 2023-04-27 · Advanced Solid Tumor, Colorectal Cancer, Lung Cancer, Squamous Cell Carcinoma of the Esophagus, Gastric Cancer, Bladder Cancer
What this study did
NCT03256344 · Amgen
2018-03-19 – 2021-12-03 · Metastatic Triple Negative Breast Cancer, Metastatic Colorectal Cancer
What this study did
NCT02876224 · Hoffmann-La Roche
2016-09-30 – 2019-06-25 · Colorectal Cancer
What this study did
Hepatocellular Carcinoma
NCT05096715 · Massachusetts General Hospital
2022-08-23 – 2032-01-31 · Unresectable Hepatocellular Carcinoma
What this study did
NCT05546879 · University Hospital, Grenoble
2023-03-15 – 2029-03-19 · Hepatocellular Carcinoma
What this study did
NCT06478693 · Myeloid Therapeutics
2024-07-01 – 2028-05-31 · Hepatocellular Carcinoma
What this study did
NCT05097911 · National University Hospital, Singapore
2021-08-02 – 2027-04 · Advanced Hepatocellular Carcinoma
What this study did
NCT05488522 · Abramson Cancer Center at Penn Medicine
2022-09-01 – 2026-12-31 · Hepatocellular Carcinoma
What this study did
NCT04857684 · Massachusetts General Hospital
2021-06-18 – 2026-12-31 · Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
What this study did
NCT05092373 · M.D. Anderson Cancer Center
2022-04-29 – 2026-09-01 · Advanced Breast Carcinoma, Advanced Endometrial Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Malignant Abdominal Neoplasm, Advanced Malignant Female Reproductive System Neoplasm, Advanced Malignant Thoracic Neoplasm, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Renal Cell Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Malignant Abdominal Neoplasm, Malignant Solid Neoplasm, Metastatic Breast Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Malignant Abdominal Neoplasm, Metastatic Malignant Female Reproductive System Neoplasm, Metastatic Malignant Thoracic Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Metastatic Renal Cell Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
What this study did
NCT05022927 · Chugai Pharmaceutical
2021-06-01 – 2025-12-31 · Hepatocellular Carcinoma (HCC)
What this study did
NCT05093608 · H. Lee Moffitt Cancer Center and Research Institute
2021-11-03 – 2022-10-12 · Hepatocellular Carcinoma
What this study did
Melanoma
NCT04020809 · The Methodist Hospital Research Institute
2020-09-25 – 2026-10-01 · Cutaneous Melanoma
What this study did
NCT04109456 · InxMed (Shanghai) Co., Ltd.
2020-03-16 – 2024-12-20 · Metastatic Melanoma
What this study did
NCT04096638 · invoX Pharma Limited
2019-09-23 – 2024-07-16 · Melanoma, Head and Neck Squamous Cell Carcinoma, Solid Tumor
What this study did
Non-Small Cell Lung Cancer
NCT06332755 · LG Chem
2024-06-05 – 2028-12 · Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial Carcinoma, Malignant Melanoma
What this study did
NCT05334329 · University of California, Irvine
2022-07-20 – 2028-11-30 · Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT05581004 · Genentech, Inc.
2022-10-20 – 2028-07-31 · Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Colorectal Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
What this study did
NCT06066138 · National Cancer Institute (NCI)
2025-11-04 – 2028-01-31 · Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Locally Advanced Small Cell Lung Cancer, Metastatic Small Cell Lung Cancer, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Locally Advanced Melanoma, Metastatic Melanoma
What this study did
NCT04449874 · Genentech, Inc.
2020-07-29 – 2027-12-31 · Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
What this study did
NCT06444815 · KaliVir Immunotherapeutics
2024-09-16 – 2027-12-31 · Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Urothelial Carcinoma Bladder, Squamous Cell Carcinoma
What this study did
NCT06616623 · Dwight Owen
2024-12-31 – 2027-12-01 · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT03170960 · Exelixis
2017-09-05 – 2027-09-30 · Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer
What this study did
NCT04919369 · Dwight Owen
2021-10-18 – 2026-07-03 · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT03289962 · Genentech, Inc.
2017-12-21 – 2025-07-01 · Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Renal Cancer, Head and Neck Cancer, Other Solid Cancers
What this study did
NCT04911166 · The Methodist Hospital Research Institute
2021-10-14 – 2025-04-01 · Non-small Cell Lung Cancer
What this study did
NCT05259319 · Centre Georges Francois Leclerc
2022-12-05 – 2024-12-05 · Metastatic Non Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Renal Cell Carcinoma, Metastatic Head and Neck Cancer
What this study did
NCT04432207 · Imugene Limited
2020-11-30 – 2024-11-07 · Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Squamous Non-small-cell Lung Cancer, Large Cell Carcinoma Lung, Adenocarcinoma Lung
What this study did
NCT04081688 · Rutgers, The State University of New Jersey
2019-09-11 – 2024-04-30 · Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT02599454 · Megan Daly, MD
2018-04-26 – 2024-02-20 · Stage I Non-Small Cell Lung Cancer
What this study did
NCT05395052 · Fate Therapeutics
2022-05-31 – 2023-08-11 · Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
What this study did
NCT03841110 · Fate Therapeutics
2019-02-15 – 2022-11-15 · Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma
What this study did
NCT03498222 · Queen Mary University of London
2018-06-01 – 2021-12-31 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02400814 · Megan Daly, MD
2015-12-03 – 2021-09-29 · Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
What this study did
NCT02013219 · Hoffmann-La Roche
2014-04-03 – 2020-02-05 · Non-Small Cell Lung Cancer
What this study did
NCT03455556 · Mayo Clinic
2018-08-10 – 2020-01-07 · Mesothelin Positive, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
What this study did
NCT03438318 · Regeneron Pharmaceuticals
2018-03-15 – 2019-12-11 · Non Small Cell Lung Cancer
What this study did
NCT02463994 · University of Michigan Rogel Cancer Center
2015-10 – 2018-11-07 · Non-small Cell Lung Cancer
What this study did
NCT02919449 · Vyriad, Inc.
2017-08-03 – 2018-01-19 · Recurrent Non-Small Cell Lung Cancer
What this study did
NCT02298153 · Incyte Corporation
2015-01-27 – 2017-11-08 · NSCLC (Non-small Cell Lung Carcinoma), UC (Urothelial Cancer)
What this study did
Phase 4 (7)
Hepatocellular Carcinoma
NCT05185505 · The Methodist Hospital Research Institute
2023-01-30 – 2028-10-31 · Hepatocellular Carcinoma, Hepatocellular Cancer
What this study did
NCT07059494 · Icahn School of Medicine at Mount Sinai
2026-03-26 – 2028-08-01 · Hepatocellular Carcinoma
What this study did
NCT05717400 · M.D. Anderson Cancer Center
2023-03-17 – 2024-08-29 · Liver Cancer
What this study did
Non-Small Cell Lung Cancer
NCT05689671 · Nikolaj Frost MD
2023-12-06 – 2026-10 · Non-Small Cell Lung Cancer Metastatic
What this study did
Other / comorbidity
NCT06031233 · Isala
2023-09-01 – 2028-12 · Oncology, Infusion Reaction
What this study did
NCT04059887 · Chonnam National University Hospital
2019-12-18 – 2022-06-30 · Lung Neoplasm Malignant
What this study did
Early phase / not applicable (13)
Bladder Cancer
NCT03577132 · Seoul National University Hospital
2018-08-01 – 2022-05-31 · Urothelial Carcinoma
What this study did
Hepatocellular Carcinoma
NCT07281664 · Third Affiliated Hospital, Sun Yat-Sen University
2026-01-01 – 2029-12-31 · Hepatocellular Carcinoma, Transarterial Chemoembolization
What this study did
NCT07543510 · Third Affiliated Hospital, Sun Yat-Sen University
2026-05-01 – 2029-08-31 · Hepatocellular Carcinoma, Atezolizumab Plus Bevacizumab, Transarterial Chemoembolization
What this study did
NCT06595108 · Yonsei University
2024-05-28 – 2028-03-27 · Advanced Hepatocellular Carcinoma, Chemotherapy, Stereotactic Body Radiotherapy
What this study did
NCT04180072 · National Health Research Institutes, Taiwan
2020-03-12 – 2026-12-31 · Carcinoma, Hepatocellular
What this study did
NCT06961526 · Tanta University
2025-02-15 – 2026-07 · Esophageal and/or Gastric Varices, Hepatocellular Carcinoma (HCC)
What this study did
NCT06609863 · Sun Yat-sen University
2024-10-01 – 2026-06-30 · Advanced Hepatocellular Carcinoma, Atezolizumab, Bevacizumab, Chemotherapy
What this study did
NCT05705791 · Gustave Roussy, Cancer Campus, Grand Paris
2023-02-07 – 2025-12-24 · Hepatocellular Carcinoma
What this study did
NCT07272265 · Sun Yat-sen University
2020-10-28 – 2025-11-10 · Hepatocellular Carcinoma (HCC)
What this study did
Other / comorbidity
NCT02453984 · University Medical Center Groningen
2016-02-24 – 2024-06 · Locally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 Expression
What this study did
NCT04801966 · Peter MacCallum Cancer Centre, Australia
2021-09-23 – 2022-12-30 · Cancer
What this study did
NCT03850028 · University Medical Center Groningen
2019-05-22 – 2022-05-01 · Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
What this study did
Used as active comparator (17)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (8)
Hepatocellular Carcinoma
NCT06921785 · AstraZeneca
2025-05-06 – 2030-03-15 · Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT07195695 · Boehringer Ingelheim
2026-01-16 – 2036-09-02 · Non-small Cell Lung Cancer
What this study did
NCT06908993 · Intergroupe Francophone de Cancerologie Thoracique
2025-12-09 – 2028-07-15 · Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation
What this study did
Small Cell Lung Cancer
NCT06712355 · BioNTech SE
2025-02-03 – 2029-07 · Extensive-stage Small-cell Lung Cancer
What this study did
NCT05224141 · Merck Sharp & Dohme LLC
2022-03-24 – 2027-06-07 · Small Cell Lung Carcinoma
What this study did
Other / comorbidity
NCT03452137 · Hoffmann-La Roche
2018-04-03 – 2024-03-06 · Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
What this study did
Phase 2/3 (2)
Phase 2 (4)
Small Cell Lung Cancer
NCT05468489 · Shanghai Henlius Biotech
2022-11-18 – 2027-12-31 · Extensive Stage Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT03756298 · National Cancer Center, Korea
2019-01-15 – 2027-12-31 · Triple Negative Breast Cancer
What this study did
NCT05180006 · Gustave Roussy, Cancer Campus, Grand Paris
2022-02-24 – 2024-12-17 · Breast Cancer
What this study did
Phase 1/2 (3)
Non-Small Cell Lung Cancer
NCT03337698 · Hoffmann-La Roche
2017-12-27 – 2025-11-25 · Carcinoma, Non-Small-Cell Lung
What this study did
Other / comorbidity
NCT06584071 · Biotheus Inc.
2024-12 – 2027-12 · HCC, Liver Cancer
What this study did
NCT06157827 · Nanjing Leads Biolabs Co.,Ltd
2023-12-08 – 2027-03-28 · Advanced Neuroendocrine Carcinoma
What this study did
Appears in other studies (31)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (9)
Hepatocellular Carcinoma
NCT07166406 · NRG Oncology
2026-02-26 – 2034-03-10 · Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
What this study did
NCT05904886 · Hoffmann-La Roche
2023-09-14 – 2026-09-01 · Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT05317858 · InSightec
2022-08-12 – 2031-12-01 · Brain Tumor, Non Small Cell Lung Cancer
What this study did
Small Cell Lung Cancer
NCT06719336 · Anhui Shi, MD
2024-12-16 – 2028-12-16 · Extensive-stage Small Cell Lung Cancer
What this study did
NCT04665856 · Hoffmann-La Roche
2020-12-21 – 2025-11-17 · Small Cell Lung Carcinoma
What this study did
NCT04256421 · Hoffmann-La Roche
2020-02-04 – 2025-07-31 · Small Cell Lung Cancer
What this study did
Phase 2/3 (2)
Hepatocellular Carcinoma
NCT07293468 · Tuen Mun Hospital
2024-04-01 – 2034-12-31 · Hepatocellular Carcinoma (HCC)
What this study did
Small Cell Lung Cancer
NCT04402788 · National Cancer Institute (NCI)
2021-01-07 – 2027-04-30 · Extensive Stage Lung Small Cell Carcinoma
What this study did
Phase 2 (15)
Bladder Cancer
NCT03693014 · Memorial Sloan Kettering Cancer Center
2018-10-01 – 2027-10 · Metastatic Cancer, Melanoma Cancer, Lung Cancer, Bladder Cancer, Renal Cancer, Head/Neck Cancers
What this study did
Hepatocellular Carcinoma
NCT05690048 · Michael Dill
2025-07-16 – 2028-03 · Immunotherapy, HCC - Hepatocellular Carcinoma
What this study did
NCT07157969 · Peking Union Medical College Hospital
2025-02-19 – 2027-06-30 · HCC - Hepatocellular Carcinoma
What this study did
Melanoma
NCT05060003 · Washington University School of Medicine
2022-11-08 – 2023-11-27 · Stage II Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT06463665 · Genelux Corporation
2024-09-26 – 2029-07 · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
What this study did
NCT03563716 · Genentech, Inc.
2018-08-10 – 2025-11-14 · Non-small Cell Lung Cancer
What this study did
NCT03511391 · University Hospital, Ghent
2018-03-09 – 2024-01-23 · Urothelial Carcinoma, Melanoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Head and Neck Cancer
What this study did
Small Cell Lung Cancer
NCT07172412 · Tianjin Medical University Cancer Institute and Hospital
2025-11 – 2028-12 · Extensive Stage Lung Small Cell Cancer
What this study did
NCT04334941 · National Cancer Institute (NCI)
2020-07-20 – 2027-01-21 · Extensive Stage Lung Small Cell Carcinoma
What this study did
Other / comorbidity
NCT04677504 · Hoffmann-La Roche
2021-02-23 – 2023-08-25 · Biliary Tract Cancer
What this study did
NCT03395899 · Queen Mary University of London
2017-12-21 – 2023-08-18 · Breast Cancer, Estrogen Receptor-positive Breast Cancer
What this study did
NCT03979066 · Gulam Manji
2019-11-01 – 2019-11-03 · Pancreatic Ductal Adenocarcinoma
What this study did
NCT02609984 · Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2015-04-29 – 2019-02-06 · Sarcoma, Myxoid/Round Cell Liposarcoma, Synovial Sarcoma, Metastatic Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Locally Advanced Sarcoma, Liposarcoma
What this study did
Phase 1/2 (2)
Small Cell Lung Cancer
NCT03830918 · Jonsson Comprehensive Cancer Center
2019-03-06 – 2027-01-03 · Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
Other / comorbidity
NCT03721679 · Oncovir, Inc.
2018-09-25 – 2021-01-26 · Solid Cancer
What this study did
Phase 1 (2)
Non-Small Cell Lung Cancer
NCT06097962 · Base Therapeutics (Shanghai) Co., Ltd.
2023-07-01 – 2028-07-01 · NSCLC
What this study did
Other / comorbidity
NCT06098898 · Base Therapeutics (Shanghai) Co., Ltd.
2023-11-01 – 2024-11-01 · Gastric Cancer
What this study did
Early phase / not applicable (1)
Hepatocellular Carcinoma
NCT05984511 · Third Affiliated Hospital, Sun Yat-Sen University
2023-08-30 – 2029-08-01 · Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Bladder Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Atezolizumab: this drugApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Avelumab
Approved(overall)
Monoclonal antibodyPD-L1
not yet graded(overall)
No reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Enfortumab VedotinApprovedAntibody–drug conjugateNectin-4Partial signal
NCT03474107: Overall Survival (OS) (From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)): Enfortumab Vedotin 1.25 mg/kg 12.88 months (95% CI 10.58 to 15.21) | Chemotherapy 8.97 months (95% CI 8.05 to 10.74)
NCT03219333: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) (Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)): Enfortumab Vedotin - Cohort 1 44 Percentage of Participants (95% CI 35.1 to 53.2) | Enfortumab Vedotin - Cohort 2 51.7 Percentage of Participants (95% CI 40.8 to 62.4)
Nogapendekin Alfa Inbakicept (Anktiva)ApprovedProtein / enzyme therapeuticIL-15 superagonistnot yet gradedNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
CetrelimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
TremelimumabPhase 3Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
VisugromabPhase 2Monoclonal antibodyGDF-15Weak signal
NCT06059547: Two primary endpoints, no significance test reported (exploratory). Pathologic complete response: 33.3% nivolumab + visugromab (n=15 evaluable) vs 7.1% nivolumab + placebo (n=14 evaluable). Objective response by RECIST 1.1: 60.0% vs 14.3%. Major pathologic response (secondary): 66.7% vs 21.4%.
MK-3120Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-2005Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
IBC-Ab002
Phase 1(overall)
Monoclonal antibodyPD-L1
Partial signal(overall)
No reviewed efficacy summary in this indication
TuvutromstatPhase 1Small moleculeMAT2Anot yet gradedNo reviewed efficacy summary in this indication
Avipendekin Pegol
—(overall)
CytokineIL-15 receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(208 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Atezolizumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (26)
November 2026 (7)
Phase 1Newly Diagnosed H3-mutated GliomaActive not recruiting
Est. primary completion 2026-11 · NCT04808245 · CT.gov ↗
What to watch
Phase 2Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 …Active not recruiting
Est. primary completion 2026-11 · NCT05168618 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-11 · NCT04958811 · CT.gov ↗
What to watch
Phase 1Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid NeoplasmActive not recruiting
Est. primary completion 2026-11-21 · NCT02862275 · CT.gov ↗
What to watch
Phase 1Recurrent GlioblastomaRecruiting
Est. primary completion 2026-11-27 · NCT07538128 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-11-30 · NCT04302025 · CT.gov ↗
What to watch
Phase 3CancerActive not recruiting
Est. primary completion 2026-11-30 · NCT03148418 · CT.gov ↗
What to watch
December 2026 (19)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT04691817 · CT.gov ↗
What to watch
Phase 1/2Bladder CancerRecruiting
Est. primary completion 2026-12 · NCT05000294 · CT.gov ↗
What to watch
Phase 1/2Bladder CancerActive not recruiting
Est. primary completion 2026-12 · NCT02989584 · CT.gov ↗
What to watch
Phase 2HER2-positive Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT03125928 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT03786692 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT03915678 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-01 · NCT07192185 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12-01 · NCT05825625 · CT.gov ↗
What to watch
Phase 1/2Relapsed or Refractory Hodgkin's LymphomaActive not recruiting
Est. primary completion 2026-12-15 · NCT05300282 · CT.gov ↗
What to watch
Phase 2Triple Negative Breast CancerRecruiting
Est. primary completion 2026-12-15 · NCT06690840 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-15 · NCT06771518 · CT.gov ↗
What to watch
Phase 3Invasive Breast CancerActive not recruiting
Est. primary completion 2026-12-15 · NCT03595592 · CT.gov ↗
What to watch
Phase 2Oropharynx Cancer, Stage IRecruiting
Est. primary completion 2026-12-16 · NCT06254911 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C MutationActive not recruiting
Est. primary completion 2026-12-17 · NCT04185883 · CT.gov ↗
What to watch
Phase 2Sarcoma,Soft TissueActive not recruiting
Est. primary completion 2026-12-30 · NCT03474094 · CT.gov ↗
What to watch
Phase 2Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNARecruiting
Est. primary completion 2026-12-30 · NCT04434040 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT05488522 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT05340309 · CT.gov ↗
What to watch
Phase 2Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 …Active not recruiting
Est. primary completion 2026-12-31 · NCT03784326 · CT.gov ↗
What to watch
2027 (92)
January 2027 (8)
Phase 1Small Cell Lung CancerRecruiting
Est. primary completion 2027-01 · NCT06807632 · CT.gov ↗
What to watch
Phase 1/2Solid Tumor, RhabdomyosarcomaActive not recruiting
Est. primary completion 2027-01 · NCT04796012 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-01 · NCT04467723 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-01 · NCT06731270 · CT.gov ↗
What to watch
Phase 2Hepato Cellular Carcinoma (HCC)Recruiting
Est. primary completion 2027-01-01 · NCT07276100 · CT.gov ↗
What to watch
Phase 1Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01-27 · NCT04560972 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-01-31 · NCT05096715 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-31 · NCT06066138 · CT.gov ↗
What to watch
February 2027 (4)
Phase 2Bladder CancerActive not recruiting
Est. primary completion 2027-02 · NCT04186013 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-02 · NCT05798663 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-02-15 · NCT05377034 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia …Active not recruiting
Est. primary completion 2027-02-28 · NCT02846623 · CT.gov ↗
What to watch
March 2027 (7)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-03 · NCT07246668 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-03 · NCT05516628 · CT.gov ↗
What to watch
Phase 2/3Colorectal CancerActive not recruiting
Est. primary completion 2027-03 · NCT05141721 · CT.gov ↗
What to watch
Phase 1Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin NeoplasmActive not recruiting
Est. primary completion 2027-03-31 · NCT04387084 · CT.gov ↗
What to watch
Phase 1Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-03-31 · NCT06077500 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2027-03-31 · NCT06830694 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2027-03-31 · NCT04873362 · CT.gov ↗
What to watch
April 2027 (5)
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2027-04 · NCT05118724 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2027-04-06 · NCT05434234 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular CarcinomaRecruiting
Est. primary completion 2027-04-25 · NCT06595108 · CT.gov ↗
What to watch
Phase 2Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate CancerRecruiting
Est. primary completion 2027-04-30 · NCT03821246 · CT.gov ↗
What to watch
Phase 4Hepatocellular CarcinomaEnrolling by invitation
Est. primary completion 2027-04-30 · NCT05185505 · CT.gov ↗
What to watch
May 2027 (9)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-05 · NCT03896074 · CT.gov ↗
What to watch
Phase 2Advanced Solid TumorRecruiting
Est. primary completion 2027-05 · NCT03767075 · CT.gov ↗
What to watch
Phase 2Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma …Recruiting
Est. primary completion 2027-05-01 · NCT05333458 · CT.gov ↗
What to watch
Phase 1Cancer-NeoplasmsActive not recruiting
Est. primary completion 2027-05-12 · NCT06537310 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-05-25 · NCT05440708 · CT.gov ↗
What to watch
Phase 1Small Cell Lung CancerRecruiting
Est. primary completion 2027-05-30 · NCT06179069 · CT.gov ↗
What to watch
Phase 2Gastric Cancer, Gastroesophageal Junction AdenocarcinomaActive not recruiting
Est. primary completion 2027-05-31 · NCT03421288 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-05-31 · NCT04721132 · CT.gov ↗
What to watch
Phase 2Triple Negative Breast CancerActive not recruiting
Est. primary completion 2027-05-31 · NCT05498896 · CT.gov ↗
What to watch
June 2027 (11)
Phase 1Osteosarcoma, Pulmonary Recurrence of OsteosarcomaRecruiting
Est. primary completion 2027-06 · NCT06492954 · CT.gov ↗
What to watch
Phase 2Prostate CancerRecruiting
Est. primary completion 2027-06-01 · NCT04812366 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06-01 · NCT04310020 · CT.gov ↗
What to watch
Phase 3Colorectal CancerActive not recruiting
Est. primary completion 2027-06-01 · NCT02997228 · CT.gov ↗
What to watch
Phase 1Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma …Active not recruiting
Est. primary completion 2027-06-30 · NCT03321643 · CT.gov ↗
What to watch
Phase 1/2Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung CancerRecruiting
Est. primary completion 2027-06-30 · NCT06110572 · CT.gov ↗
What to watch
Phase 1/2Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related ChangesActive not recruiting
Est. primary completion 2027-06-30 · NCT02935361 · CT.gov ↗
What to watch
Phase 2Neoplasm MetastasisActive not recruiting
Est. primary completion 2027-06-30 · NCT00781612 · CT.gov ↗
What to watch
Phase 2Bladder CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT03237780 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT03178552 · CT.gov ↗
What to watch
Phase 3NeoplasmsActive not recruiting
Est. primary completion 2027-06-30 · NCT05112965 · CT.gov ↗
What to watch
July 2027 (14)
Phase 1Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-07 · NCT05595460 · CT.gov ↗
What to watch
Phase 3Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-07 · NCT04803994 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2027-07-01 · NCT04696575 · CT.gov ↗
What to watch
Phase 2CancerActive not recruiting
Est. primary completion 2027-07-01 · NCT06754501 · CT.gov ↗
What to watch
Phase 2Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8Active not recruiting
Est. primary completion 2027-07-01 · NCT05411081 · CT.gov ↗
What to watch
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2027-07-20 · NCT06362252 · CT.gov ↗
What to watch
Phase 1PIK3CA-Mutated CancersActive not recruiting
Est. primary completion 2027-07-21 · NCT06496568 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumor, LymphomaActive not recruiting
Est. primary completion 2027-07-30 · NCT05878691 · CT.gov ↗
What to watch
Phase 1/2Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic …Active not recruiting
Est. primary completion 2027-07-30 · NCT07280377 · CT.gov ↗
What to watch
Phase 1/2Advanced Liver CancersActive not recruiting
Est. primary completion 2027-07-30 · NCT04524871 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-07-30 · NCT06096779 · CT.gov ↗
What to watch
Phase 3Mesotheliomas PleuralRecruiting
Est. primary completion 2027-07-30 · NCT04996017 · CT.gov ↗
What to watch
Phase 2Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8 …Active not recruiting
Est. primary completion 2027-07-31 · NCT03181100 · CT.gov ↗
What to watch
Phase 2Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck CancerActive not recruiting
Est. primary completion 2027-07-31 · NCT03708224 · CT.gov ↗
What to watch
August 2027 (5)
Phase 1Glioblastoma MultiformeRecruiting
Est. primary completion 2027-08 · NCT05423210 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-08 · NCT06695026 · CT.gov ↗
What to watch
Phase 2Peritoneal Malignant MesotheliomaRecruiting
Est. primary completion 2027-08-01 · NCT05001880 · CT.gov ↗
What to watch
Phase 4Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-08-01 · NCT07059494 · CT.gov ↗
What to watch
Phase 3Venous ThrombosisActive not recruiting
Est. primary completion 2027-08-31 · NCT04649489 · CT.gov ↗
What to watch
September 2027 (6)
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-09-01 · NCT07774247 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-09-01 · NCT04253964 · CT.gov ↗
What to watch
Phase 1Locally Advanced Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Unresectable Skin Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-09-10 · NCT05085496 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-09-30 · NCT06444815 · CT.gov ↗
What to watch
Phase 2Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma …Active not recruiting
Est. primary completion 2027-09-30 · NCT03074513 · CT.gov ↗
What to watch
October 2027 (6)
Phase 1/2Malignant Pleural MesotheliomaRecruiting
Est. primary completion 2027-10 · NCT05765084 · CT.gov ↗
What to watch
Phase 2Bladder CancerRecruiting
Est. primary completion 2027-10 · NCT05312671 · CT.gov ↗
What to watch
Phase 2Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST) …Active not recruiting
Est. primary completion 2027-10 · NCT05152472 · CT.gov ↗
What to watch
Phase 2Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Gynecologic Cancer, Sarcoma, Unknown Primary Tumors …Active not recruiting
Est. primary completion 2027-10 · NCT04273061 · CT.gov ↗
What to watch
Phase 1Solid TumorRecruiting
Est. primary completion 2027-10-31 · NCT05907980 · CT.gov ↗
What to watch
Phase 2Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part SarcomaActive not recruiting
Est. primary completion 2027-10-31 · NCT03141684 · CT.gov ↗
What to watch
November 2027 (3)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11 · NCT06332755 · CT.gov ↗
What to watch
Phase 2Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract, Squamous Cell Carcinoma of the Bladder …Recruiting
Est. primary completion 2027-11-01 · NCT06161532 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-11-10 · NCT07239245 · CT.gov ↗
What to watch
December 2027 (14)
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT05652686 · CT.gov ↗
What to watch
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT05703971 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT07654400 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-12-01 · NCT05733598 · CT.gov ↗
What to watch
Phase 2/3Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma …Active not recruiting
Est. primary completion 2027-12-15 · NCT05063552 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-30 · NCT04919382 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT06478693 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT04449874 · CT.gov ↗
What to watch
Phase 1/2Recurrent Glioblastoma, Recurrent GliosarcomaActive not recruiting
Est. primary completion 2027-12-31 · NCT05039281 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Locally Advanced Osteosarcoma, Metastatic Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma, Unresectable OsteosarcomaRecruiting
Est. primary completion 2027-12-31 · NCT05019703 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT02693535 · CT.gov ↗
What to watch
Phase 2Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory CarcinomaActive not recruiting
Est. primary completion 2027-12-31 · NCT03202316 · CT.gov ↗
What to watch
Phase 2Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma …Recruiting
Est. primary completion 2027-12-31 · NCT04981509 · CT.gov ↗
What to watch
2028 (44)
January 2028 (9)
Phase 1/2Solid CancerActive not recruiting
Est. primary completion 2028-01-01 · NCT06771622 · CT.gov ↗
What to watch
Phase 2Recurrent GlioblastomaRecruiting
Est. primary completion 2028-01-01 · NCT06069726 · CT.gov ↗
What to watch
Phase 2Solid Tumor, AdultActive not recruiting
Est. primary completion 2028-01-01 · NCT06003621 · CT.gov ↗
What to watch
Phase 2Soft Tissue SarcomaRecruiting
Est. primary completion 2028-01-01 · NCT07049848 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic Leukemia, Richter's TransformationRecruiting
Est. primary completion 2028-01-15 · NCT06043674 · CT.gov ↗
What to watch
Phase 1/2Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-01-28 · NCT04471727 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-01-30 · NCT06294548 · CT.gov ↗
What to watch
Phase 2Large Cell Neuroendocrine Carcinoma of the LungActive not recruiting
Est. primary completion 2028-01-31 · NCT05470595 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-01-31 · NCT02525757 · CT.gov ↗
What to watch
February 2028 (4)
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2028-02 · NCT04727307 · CT.gov ↗
What to watch
Phase 1Endometrial Cancer, Metastasis, Endometrioid Endometrial Cancer, Carcinosarcoma, Serous Adenocarcinoma of Endometrium (Diagnosis) …Recruiting
Est. primary completion 2028-02-21 · NCT05542407 · CT.gov ↗
What to watch
Phase 1/2Advanced Cholangiocarcinoma, FGFR2 FusionRecruiting
Est. primary completion 2028-02-22 · NCT06439485 · CT.gov ↗
What to watch
Phase 2Ovarian CancerActive not recruiting
Est. primary completion 2028-02-28 · NCT04931342 · CT.gov ↗
What to watch
March 2028 (4)
Phase 1Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid TumorsActive not recruiting
Est. primary completion 2028-03-01 · NCT06031441 · CT.gov ↗
What to watch
Phase 1/2Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-03-07 · NCT05142696 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-03-27 · NCT05528952 · CT.gov ↗
What to watch
Phase 2Glioblastoma, Recurrence TumorRecruiting
Est. primary completion 2028-03-30 · NCT07263438 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3Colorectal CancerRecruiting
Est. primary completion 2028-04-01 · NCT06733038 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2MelanomaActive not recruiting
Est. primary completion 2028-06-30 · NCT03175432 · CT.gov ↗
What to watch
July 2028 (5)
Phase 1Colorectal CancerRecruiting
Est. primary completion 2028-07 · NCT06012734 · CT.gov ↗
What to watch
Phase 4Oncology, Infusion ReactionRecruiting
Est. primary completion 2028-07 · NCT06031233 · CT.gov ↗
What to watch
Phase 3Advanced CancerNot yet recruiting
Est. primary completion 2028-07-03 · NCT07929051 · CT.gov ↗
What to watch
Phase 3CancerActive not recruiting
Est. primary completion 2028-07-05 · NCT03768063 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-07-31 · NCT05581004 · CT.gov ↗
What to watch
August 2028 (2)
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2028-08-30 · NCT06663098 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-08-31 · NCT07543510 · CT.gov ↗
What to watch
September 2028 (3)
Phase 3Small Cell Lung CancerRecruiting
Est. primary completion 2028-09-09 · NCT07472517 · CT.gov ↗
What to watch
Phase 1Advanced Solid MalignanciesActive not recruiting
Est. primary completion 2028-09-15 · NCT06760481 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-09-30 · NCT06133062 · CT.gov ↗
What to watch
October 2028 (4)
Phase 2Cervical Cancer, Cervical Cancer Recurrent, Cervical Cancer MetastaticActive not recruiting
Est. primary completion 2028-10 · NCT03614949 · CT.gov ↗
What to watch
Phase 2/3Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma …Recruiting
Est. primary completion 2028-10-01 · NCT05058651 · CT.gov ↗
What to watch
Phase 1NeoplasmsRecruiting
Est. primary completion 2028-10-16 · NCT06551142 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-10-27 · NCT06789757 · CT.gov ↗
What to watch
November 2028 (3)
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2028-11 · NCT07407933 · CT.gov ↗
What to watch
Phase 2Squamous Cell Carcinoma, Oral Cavity Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2028-11-01 · NCT05681039 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-11-30 · NCT05334329 · CT.gov ↗
What to watch
December 2028 (8)
Phase 1Treatment-Refractory Solid TumorsNot yet recruiting
Est. primary completion 2028-12 · NCT07170592 · CT.gov ↗
What to watch
Phase 1Treatment-Refractory Solid TumorsRecruiting
Est. primary completion 2028-12 · NCT07190833 · CT.gov ↗
What to watch
Phase 3Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-12 · NCT06680258 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-12-05 · NCT07317414 · CT.gov ↗
What to watch
Phase 1/2Metastatic MalignancyActive not recruiting
Est. primary completion 2028-12-31 · NCT05394337 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerRecruiting
Est. primary completion 2028-12-31 · NCT05944237 · CT.gov ↗
What to watch
Phase 2Rectal CancerActive not recruiting
Est. primary completion 2028-12-31 · NCT04017455 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07281664 · CT.gov ↗
What to watch
2029 (17)
February 2029 (2)
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2029-02-01 · NCT07339059 · CT.gov ↗
What to watch
Phase 3Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2029-02-01 · NCT04712643 · CT.gov ↗
What to watch
March 2029 (3)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-03-30 · NCT06339424 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-03-31 · NCT07010497 · CT.gov ↗
What to watch
Phase 2HCCRecruiting
Est. primary completion 2029-03-31 · NCT06823375 · CT.gov ↗
What to watch
April 2029 (3)
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2029-04 · NCT07155174 · CT.gov ↗
What to watch
Phase 2Cancer, Tumors, Neoplasms, NeoplasiaRecruiting
Est. primary completion 2029-04-30 · NCT04341181 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-04-30 · NCT06632327 · CT.gov ↗
What to watch
May 2029 (1)
Phase 1/2Inoperable, Locally Advanced or Metastatic, ER-positive Breast CancerRecruiting
Est. primary completion 2029-05-30 · NCT04802759 · CT.gov ↗
What to watch
June 2029 (2)
Phase 3Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2029-06-01 · NCT07461675 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-06-30 · NCT06605664 · CT.gov ↗
What to watch
July 2029 (1)
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2029-07-25 · NCT06287775 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-08-31 · NCT03228667 · CT.gov ↗
What to watch
September 2029 (1)
Phase 1Small Cell Lung CancerRecruiting
Est. primary completion 2029-09-30 · NCT07545954 · CT.gov ↗
What to watch
October 2029 (3)
Phase 2/3Colorectal CancerRecruiting
Est. primary completion 2029-10 · NCT05770102 · CT.gov ↗
What to watch
Phase 2/3Haematological Malignancy, Solid TumourRecruiting
Est. primary completion 2029-10 · NCT05722886 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2029-10-01 · NCT07835737 · CT.gov ↗
What to watch
2030 (13)
January 2030 (3)
Phase 1Small Cell Lung CancerRecruiting
Est. primary completion 2030-01 · NCT07113691 · CT.gov ↗
What to watch
Phase 3Small Cell Lung CancerRecruiting
Est. primary completion 2030-01 · NCT07625644 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-01-01 · NCT06254248 · CT.gov ↗
What to watch
March 2030 (2)
Phase 2Early-stage Breast CancerRecruiting
Est. primary completion 2030-03 · NCT05332561 · CT.gov ↗
What to watch
Phase 1/2Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm …Active not recruiting
Est. primary completion 2030-03-31 · NCT05286801 · CT.gov ↗
What to watch
April 2030 (1)
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2030-04-26 · NCT07707895 · CT.gov ↗
What to watch
May 2030 (2)
Phase 1Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-05-30 · NCT05361395 · CT.gov ↗
What to watch
Phase 3Colorectal CancerEnrolling by invitation
Est. primary completion 2030-05-31 · NCT07620574 · CT.gov ↗
What to watch
August 2030 (2)
Phase 1Colorectal CancerRecruiting
Est. primary completion 2030-08-31 · NCT04929223 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-08-31 · NCT03942328 · CT.gov ↗
What to watch
September 2030 (1)
Phase 1/2Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
November 2030 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-11-01 · NCT07322341 · CT.gov ↗
What to watch
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2030-11-29 · NCT07227597 · CT.gov ↗
What to watch
2031 (8)
January 2031 (1)
Phase 2Adenocarcinoma, Pancreatic DuctalActive not recruiting
Est. primary completion 2031-01-01 · NCT05968326 · CT.gov ↗
What to watch
February 2031 (1)
Phase 3Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-02-24 · NCT07947121 · CT.gov ↗
What to watch
June 2031 (2)
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2031-06 · NCT06725121 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2031-06 · NCT07018947 · CT.gov ↗
What to watch
August 2031 (2)
Phase 2Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-08 · NCT07895056 · CT.gov ↗
What to watch
Phase 2Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor, Hedgehog InhibitorRecruiting
Est. primary completion 2031-08-30 · NCT05538091 · CT.gov ↗
What to watch
November 2031 (1)
Phase 2Advanced Cancer, Solid Tumor, Haematological MalignancyRecruiting
Est. primary completion 2031-11-25 · NCT05159245 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-12 · NCT07895043 · CT.gov ↗
What to watch
2032 (3)
June 2032 (1)
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2032-06 · NCT05468359 · CT.gov ↗
What to watch
September 2032 (2)
Phase 2Solid TumorsActive not recruiting
Est. primary completion 2032-09-25 · NCT04589845 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-09-30 · NCT07388524 · CT.gov ↗
What to watch
2033 (1)
March 2033 (1)
Phase 3CancerRecruiting
Est. primary completion 2033-03-01 · NCT05862285 · CT.gov ↗
What to watch
2035 (1)
May 2035 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2035-05-02 · NCT07153445 · CT.gov ↗
What to watch
2040 (3)
February 2040 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2040-02-28 · NCT07770100 · CT.gov ↗
What to watch
March 2040 (1)
Phase 2Cancer MetastaticRecruiting
Est. primary completion 2040-03-30 · NCT04817956 · CT.gov ↗
What to watch
July 2040 (1)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2040-07-01 · NCT05620771 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 October 2026ApprovalFDA approves Tecentriq for adjuvant stage III dMMR colon cancer
US, FDA · Roche · Source ↗
7 October 2025FDA action datePDUFA date set for October 7, 2025
US, FDA · Source ↗
2 October 2025ApprovalFDA approves Zepzelca plus atezolizumab as first-line maintenance for ES-SCLC
US, FDA · Source ↗
10 June 2025Filing acceptedFDA accepts sNDA for Zepzelca plus atezolizumab
US, FDA · Source ↗
10 June 2025Priority reviewFDA grants Priority Review
US, FDA · Source ↗